България - български - Изпълнителна агенция по лекарствата

iason gmbh - 1 gbq/ml solution for injection

България - български - Изпълнителна агенция по лекарствата

ge healthcare limited - Натриев Молибдат (99mo), Технеция (99мтс) пертехнетата - 2,5 - 100 gbq radionuclide generator

България - български - Изпълнителна агенция по лекарствата

ge healthcare buchler gmbh & co. kg - Натриев йодид [131i по] - 37 mbq - 5,55 gbq capsules, hard

България - български - Изпълнителна агенция по лекарствата

monrol europe s.r.l. - 10 - 40 gbq radionuclide generator

България - български - Изпълнителна агенция по лекарствата

2,0 gbq/ml,solution for injection

България - български - Изпълнителна агенция по лекарствата

national center for nuclear research - 8,0 - 175 gbq radionuclide generator

България - български - Изпълнителна агенция по лекарствата

2 - 50 gbq radionuclide generator

Европейски съюз - български - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Антинеопластични средства - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Европейски съюз - български - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - Антинеопластични средства - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Антинеопластични средства - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.